Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation study of liposomal mitoxantrone with CLAG in relapsed or refractory acute myeloid leukemia
ChiCTR2200060080Phase 4Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Mar 2022
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone-liposome, cladribine, cytarabine and granulocyte colony-stimulating factor in acute myeloid leukemia (AML), sponsored by Xinqiao Hospital. Primary endpoint: Maximum tolerated dose of mitoxantrone liposome. Started Mar 2022; status: recruiting.
02
Drugs
mitoxantrone-liposomecladribinecytarabinegranulocyte colony-stimulating factor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200060080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060080.